OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness
Ilaria Cavallari, Ernesto Maddaloni, Annunziata Nusca, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 263-270
Closed Access | Times Cited: 13
Ilaria Cavallari, Ernesto Maddaloni, Annunziata Nusca, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 263-270
Closed Access | Times Cited: 13
Showing 13 citing articles:
Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Heart Failure Patients: A Systematic Review and Meta-Analysis of Cost-Utility Studies
X Y Zhang, Yanxia Zhang, Jiayu Wang, et al.
Archives of Gerontology and Geriatrics (2025) Vol. 133, pp. 105809-105809
Closed Access | Times Cited: 1
X Y Zhang, Yanxia Zhang, Jiayu Wang, et al.
Archives of Gerontology and Geriatrics (2025) Vol. 133, pp. 105809-105809
Closed Access | Times Cited: 1
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Obesity (2023) Vol. 31, Iss. 6, pp. 1510-1513
Open Access | Times Cited: 22
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Obesity (2023) Vol. 31, Iss. 6, pp. 1510-1513
Open Access | Times Cited: 22
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials
Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 5, pp. 1341-1350
Closed Access | Times Cited: 17
Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 5, pp. 1341-1350
Closed Access | Times Cited: 17
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 961-964
Open Access | Times Cited: 26
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 961-964
Open Access | Times Cited: 26
Transition from asymptomatic to symptomatic systolic chronic heart failure: rationale and design of TransitionCHF
Anja Sandek, Frank Edelmann, Christoph Gertler, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 2366-2378
Open Access | Times Cited: 1
Anja Sandek, Frank Edelmann, Christoph Gertler, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 2366-2378
Open Access | Times Cited: 1
Qualitative Evaluation to Understand Barriers and Facilitators to Prescribing Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and Sodium-Glucose Cotransporter Inhibitors (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF)
Apoorva Pradhan, Mia E. Lussier, My Huong Nguyen, et al.
Journal of the American Pharmacists Association (2024) Vol. 64, Iss. 6, pp. 102224-102224
Open Access | Times Cited: 1
Apoorva Pradhan, Mia E. Lussier, My Huong Nguyen, et al.
Journal of the American Pharmacists Association (2024) Vol. 64, Iss. 6, pp. 102224-102224
Open Access | Times Cited: 1
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Ilaria Cavallari, Simone Pasquale Crispino, Andrea Segreti, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 609-621
Closed Access | Times Cited: 3
Ilaria Cavallari, Simone Pasquale Crispino, Andrea Segreti, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 609-621
Closed Access | Times Cited: 3
Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates
Signe Baattrup Reitzel, Mette Bøgelund, A Basse, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 8, pp. 1055-1060
Open Access | Times Cited: 1
Signe Baattrup Reitzel, Mette Bøgelund, A Basse, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 8, pp. 1055-1060
Open Access | Times Cited: 1
Cost-Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
Massimiliano Camilli, Federico Ballacci, Federica Giordano, et al.
Journal of Cardiovascular Pharmacology (2023)
Open Access
Massimiliano Camilli, Federico Ballacci, Federica Giordano, et al.
Journal of Cardiovascular Pharmacology (2023)
Open Access
New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients
Peter M. Nilsson, Hannes Holm, Martin Magnusson
Updates in hypertension and cardiovascular protection (2023), pp. 371-379
Closed Access
Peter M. Nilsson, Hannes Holm, Martin Magnusson
Updates in hypertension and cardiovascular protection (2023), pp. 371-379
Closed Access
Gliflozins, a new hope for heart failure? systematic review
Ana Beatriz Golin Brustolin, Rafael Porcile
SCT Proceedings in Interdisciplinary Insights and Innovations. (2023) Vol. 1, pp. 166-166
Closed Access
Ana Beatriz Golin Brustolin, Rafael Porcile
SCT Proceedings in Interdisciplinary Insights and Innovations. (2023) Vol. 1, pp. 166-166
Closed Access
SGLT-2 inhibitors most cost effective for symptomatic and asymptomatic HFrEF
PharmacoEconomics & Outcomes News (2021) Vol. 893, Iss. 1, pp. 24-24
Closed Access
PharmacoEconomics & Outcomes News (2021) Vol. 893, Iss. 1, pp. 24-24
Closed Access
